Application of brevibacillus laterosporus in degrading ochratoxin A

Abstract

The invention discloses application of brevibacillus laterosporus in degradation of ochratoxin A, and belongs to the technical field of microbiology and biodegradation. The preservation number of the brevibacillus laterosporus is CCTCC NO: M 2022932, the brevibacillus laterosporus can degrade the ochratoxin A and prepare a product for degrading the ochratoxin A, the brevibacillus laterosporus participates in degradation of the ochratoxin A in the form of viable bacteria or fermentation liquor, and the degradation rate of the brevibacillus laterosporus to the ochratoxin A is as high as 98.26%. Besides, tests prove that the brevibacillus laterosporus has an antagonistic effect on the aspergillus ochraceus and can be used for preparing an antibacterial product of the aspergillus ochraceus, so that the ochratoxin A is treated from the source.

Description

Technical Field

[0001] The present invention relates to the field of microbiology and biodegradation technology, in particular to application of a strain of Brevibacillus laterosporus in degrading ochratoxin A. Background Art

[0002] Ochratoxin A (OTA) is a secondary metabolite produced by toxin-producing strains of Aspergillus spp. and Penicillium spp., which primarily infect grains and various agricultural by-products, causing OTA contamination in crop raw materials and their processed products. OTA exhibits multiple toxicities, including nephrotoxicity, hepatotoxicity, and immunotoxicity, posing a significant potential hazard to animal and human health and is classified as a Class 2B carcinogen. OTA's primary target organs are the liver and kidneys, with the kidneys being the most sensitive to OTA, with nephrotoxicity being the most typical and earliest symptom. OTA can also cause genotoxicity, neurotoxicity, teratogenicity, and damage the immune system.

[0003] Currently, OTA detoxification methods include chemical, physical, and biological methods. Chemical detoxification methods often utilize chemicals such as organic acids, alkaline compounds, and strong oxidants to hydrolyze the lactone ring or amide bond of OTA. Physical detoxification methods include radiation, heat, and adsorption. However, in the food industry, neither physical nor chemical detoxification methods can completely degrade the toxin, limiting their application and potentially leading to nutrient loss and secondary contamination. In contrast, biological detoxification methods utilize mild conditions, do not reduce the nutritional value of food, and demonstrate excellent effectiveness and specificity in detoxifying OTA. Biodegradation utilizes microorganisms or enzymes to convert mycotoxins into less toxic chemicals such as ochratoxin α (OTα) and β-phenylalanine through biological metabolism, completely destroying the chemical structure of the mycotoxins and achieving safe and efficient detoxification.

[0004] At present, research on ochratoxin-degrading bacteria mainly focuses on bacteria such as Bacillus subtilis, Bacillus lichen iformis, Lactobacillus rhamnosus, Microbacterium sp., Acinetobacter calcoaceticus, Acinetobacter pittii, and fungi such as Yarrowia lipolytica, Saccharomyces cerevisiae, Aspergillus fumigatus, and Aspergillus niger. Research on Brevibacillus laterosporus is relatively lacking. Summary of the Invention

[0005] In response to the above-mentioned prior art, the present invention aims to provide a strain of Brevibacillus laterosporus for use in degrading ochratoxin A. The present invention is the first to discover that Brevibacillus laterosporus, deposited with CCTCC NO: M 2022932, also has the ability to degrade ochratoxin A and, moreover, has an antagonistic effect on ochratoxin A-producing strains, thus demonstrating its significance for the biodegradation of ochratoxin A.

[0006] To achieve the above object, the present invention adopts the following technical solutions:

[0007] The first aspect of the present invention provides the use of Brevibacillus laterosporus in the following (1) or (2):

[0008] (1) Degradation of ochratoxin A;

[0009] (2) Preparation of products for degrading ochratoxin A.

[0010] The Brevibacillus laterosporus used in the present invention is Brevibacillus laterosporus BLCC1-0170, which was deposited with the China Center for Type Culture Collection (CCTCC, Wuhan University, Wuhan, China) on June 20, 2022, with a deposit number of CCTCC NO: M 2022932. This strain is described in patent document CN115927058B.

[0011] The functions of Brevibacillus laterosporus BLCC1-0170 described in patent CN115927058B are: it can be used for fermentation to produce chlorogenic acid, has an antibacterial effect on five pathogenic bacteria, namely Staphylococcus aureus, Clostridium perfringens, Salmonella enteritidis, Aeromonas hydrophila and Escherichia coli, has antioxidant capacity and acid-producing properties, has a preventive effect on ulcerative colitis in mice, and has a certain intervention and relief effect on the stress state of the mouse body.

[0012] The present invention further studies Brevibacillus laterosporus BLCC1-0170 and finds that the strain can also be used to degrade ochratoxin A with excellent degradation effect, which is a new function of Brevibacillus laterosporus BLCC1-0170.

[0013] In the above application, the Brevibacillus laterosporus participates in the degradation of ochratoxin A in the form of live bacteria or fermentation liquid.

[0014] Preferably, the fermentation broth of Brevibacillus laterosporus is prepared by the following method:

[0015] The activated Brevibacillus laterosporus was inoculated into LB liquid culture medium and fermented to obtain a fermentation liquid;

[0016] The fermentation culture conditions are as follows: fermentation temperature of 35-38°C, fermentation speed of 150-200 r / min, and fermentation culture time of 12-36 hours.

[0017] Furthermore, the product for degrading ochratoxin A may also include excipients and / or carriers; for example, lactose, microcrystalline cellulose, starch, mannitol, etc. may be selected as fillers; hydroxypropyl methylcellulose may be selected as a binder; and magnesium stearate, talc, silicon dioxide, etc. may be selected as lubricants.

[0018] Furthermore, the product for degrading ochratoxin A can be prepared into various dosage forms, such as liquid, emulsion, suspension, powder, granule, wettable powder or water dispersant.

[0019] The second aspect of the present invention provides the use of the Brevibacillus laterosporus BLCC1-0170 in the preparation of an antibacterial product for Aspergillus ochraceus.

[0020] The present invention finds that Brevibacillus laterosporus BLCC1-0170 has an antagonistic effect on Aspergillus ochraceus that produces ochratoxin A, can cause the hyphae of Aspergillus ochraceus to show phenomena such as atrophy, distortion, wrinkling, protoplasm rupture, thickening and deformity, and significantly reduce the spore production ability of Aspergillus ochraceus.

[0021] Beneficial effects of the present invention:

[0022] (1) The present invention is the first to discover that Brevibacillus laterosporus BLCC1-0170, deposited with CCTCC NO: M 2022932, can be used to degrade ochratoxin A, with a degradation rate of up to 98.26%. The method of degrading OTA using this bacterium is simple and safe, overcoming the low degradation rate of existing OTA-degrading bacteria, and is of great significance in improving grain and food quality and ensuring national food safety.

[0023] (2) The present invention also discovered that Brevibacillus laterosporus BLCC1-0170, deposited with CCTCC NO: M 2022932, has a significant antagonistic effect on Aspergillus ochraceus, which produces ochratoxin A. Using Brevibacillus laterosporus BLCC1-0170, deposited with CCTCC NO: M 2022932, can control OTA at the source. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 : Liquid chromatograms of the fermentation broths corresponding to Brevibacillus laterosporus BLCC1-0170, BLCC1-1222, BLCC1-1218, BLCC1-1219, and BLCC1-1189 in Example 1;

[0025] Figure 2 : Flat plate confrontation diagram of Brevibacillus laterosporus BLCC1-0170 antagonizing Aspergillus ochra BLCC6-0076 in Example 2, wherein the left figure is a picture of the colony morphology of Aspergillus ochra BLCC6-0076 in the control group, and the right figure is a picture of the colony morphology of Aspergillus ochra BLCC6-0076 in the antagonistic group;

[0026] Figure 3: Scanning electron micrographs of Brevibacillus laterosporus BLCC1-0170 before and after antagonism against Aspergillus ochra BLCC6-0076 in Example 2, wherein (a) is an electron micrograph of Aspergillus ochra BLCC6-0076 before antagonism, and (b) is an electron micrograph of Aspergillus ochra BLCC6-0076 after antagonism;

[0027] Figure 4 : OTA residues in the liver and kidney of white-feathered broiler chickens at different feeding times in Example 3; DETAILED DESCRIPTION

[0028] It should be noted that the following detailed descriptions are illustrative and intended to provide further explanation of the present application. Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which the present application belongs.

[0029] In order to enable those skilled in the art to more clearly understand the technical solution of the present invention, the technical solution of the present invention will be described in detail below with reference to specific embodiments.

[0030] The experimental materials used in the examples of the present invention are all conventional experimental materials in the art and can be purchased through commercial channels.

[0031] The culture medium used in the present invention is as follows:

[0032] LB liquid medium: by mass percentage, glucose 0.2%, peptone 1.0%, yeast extract 0.5%, NaCl 0.5%, pH 7.0, sterilized at 121°C for 30 min.

[0033] LB solid medium: add 1.5% (mass fraction) agar powder to the above liquid medium.

[0034] PDA liquid culture medium: by mass percentage, 20% potato, 2% glucose, 0.5% peptone, 0.3% potassium dihydrogen phosphate, 0.15% magnesium sulfate, sterilized at 121°C for 30 min.

[0035] PDA solid medium: add 1.5% (mass fraction) agar powder to the above PDA liquid medium.

[0036] Brevibacillus laterosporus BLCC1-0170 was deposited in the China Center for Type Culture Collection (CCTCC, Wuhan University, Wuhan, China) on June 20, 2022, with the deposit number: CCTCC NO: M 2022932.

[0037] Example 1: Screening of ochratoxin-degrading strains

[0038] 1 Materials and Methods

[0039] 1.1 Test strains

[0040] Brevibacillus laterosporus BLCC1-0170, Brevibacillus laterosporus BLCC1-1189, Brevibacillus laterosporus BLCC1-1218, Brevibacillus laterosporus BLCC1-1219 and Brevibacillus laterosporus BLCC1-1222 preserved in the strain resource library of Shandong Baolaililai Bioengineering Co., Ltd. were used as test strains.

[0041] 1.2 Preparation of strain fermentation broth

[0042] The above test strains were activated respectively using LB solid medium slant, and a loop of the activated test strain was scraped with an inoculation loop and inoculated into 20 mL of LB liquid medium. The culture was fermented at 37°C and 180 rpm for 24 h to obtain fermentation broth, which was subsequently used for the test.

[0043] 1.3 Screening of OTA-degrading strains

[0044] A total of six treatment groups were set up, as follows:

[0045] Experimental group 1: 20 μL of Brevibacillus laterosporus BLCC1-0170 fermentation broth, 780 μL of LB liquid medium, and 200 μL of TA standard working solution were mixed to obtain a mixed solution;

[0046] Experimental group 2: 20 μL of Brevibacillus laterosporus BLCC1-1222 fermentation broth, 780 μL of LB liquid medium, and 200 μL of TA standard working solution were mixed to obtain a mixed solution;

[0047] Experimental group 3: 20 μL of Brevibacillus laterosporus BLCC1-1218 fermentation broth, 780 μL of LB liquid medium, and 200 μL of TA standard working solution were mixed to obtain a mixed solution;

[0048] Experimental group 4: 20 μL of Brevibacillus laterosporus BLCC1-1219 fermentation broth, 780 μL of LB liquid medium, and 200 μL of TA standard working solution were mixed to obtain a mixed solution;

[0049] Experimental group 5: 20 μL of Brevibacillus laterosporus BLCC1-1189 fermentation broth, 780 μL of LB liquid medium, and 200 μL of TA standard working solution were mixed to obtain a mixed solution;

[0050] Control group: 800 μL LB liquid medium and 200 μL OTA standard working solution were mixed to obtain a mixed solution;

[0051] Among them, OTA standard was purchased from Qingdao Puruibang Bioengineering Co., Ltd., and the OTA standard was dissolved in acetonitrile solution to obtain an OTA working stock solution with a concentration of 1 mg / mL. The OTA working stock solution was then diluted with sterile water to obtain an OTA standard working solution with a concentration of 5 μg / mL. The OTA standard working solution needed to be filtered through a 0.22 μm organic filter membrane before use to ensure that the final OTA concentration in each treatment group system was 1 μg / mL.

[0052] The mixed solution of each treatment group was cultured at 37°C and 180 r / min for 24 h. After the culture was completed, it was centrifuged at 4000 r / min for 5 min, and the supernatant was collected to obtain the culture solution. The culture solution was diluted 20 times with water and the OTA-degrading strain was screened by high-performance liquid chromatography. The specific steps were referred to GB / T 30957-2014 "Determination of ochratoxin A in feed - Immunoaffinity column cleanup-High-performance liquid chromatography".

[0053] The calculation formula of OTA degradation rate is:

[0054] Degradation rate (detoxification rate) = [(peak area corresponding to OTA content in the supernatant of the control group - peak area corresponding to OTA content in the supernatant of the experimental group) / peak area corresponding to OTA content in the supernatant of the control group] × 100%.

[0055] 2 Test results

[0056] The results are shown in Table 1 and Figure 1 shown.

[0057] Table 1 OTA degradation rate in the culture medium of each group

[0058]

[0059] From Table 1 and Figure 1 As can be seen, B. laterosporus BLCC1-0170 achieved a high OTA degradation rate of 98.26%, while the degradation rates of the other B. laterosporus strains were all less than 30%, and even the degradation rate of B. laterosporus BLCC1-1189 approached 0. The degradation rate of OTA by B. laterosporus BLCC1-0170 was much higher than that of the other B. laterosporus strains. Therefore, B. laterosporus BLCC1-0170 was selected as the optimal OTA-degrading strain for subsequent experiments.

[0060] Example 2: Antagonistic effect of Brevibacillus laterosporus BLCC1-0170 on OTA-producing Aspergillus ochraceus

[0061] 1 Screening of OTA-producing strains

[0062] Aspergillus niger BLCC6-0007 and Aspergillus ochraceus BLCC6-0076, which were preserved in the strain resource library of Shandong Baolaililai Bioengineering Co., Ltd., were used as experimental objects.

[0063] PDA solid culture medium slant was used to activate Aspergillus ochrae BLCC6-0076 and Aspergillus niger BLCC6-0007, respectively. A loop of activated Aspergillus ochrae BLCC6-0076 and Aspergillus niger BLCC6-0007 were scraped with an inoculation loop and inoculated into 20 mL PDA liquid culture medium, respectively. After fermentation at 28°C and 180 r / min for 72 h, the corresponding fermentation broths of Aspergillus ochrae and Aspergillus niger were obtained. The fermentation broths were centrifuged at 4000 r / min for 5 min, and the supernatants were collected. At the same time, a standard OTA working solution with a concentration of 50 μg / L was used as a control group. The OTA content in the supernatant was detected by high performance liquid chromatography. The results are shown in Table 2.

[0064] Table 2 OTA content in fermentation broth of Aspergillus niger and Aspergillus ochraceus

[0065] Group Peak area (count) control group 414793.6 Aspergillus niger BLCC6-0007 - Aspergillus ochraceus BLCC6-0076 767991.1

[0066] Note: “-” in the table means not measured.

[0067] As shown in Table 2, Aspergillus ochraceus BLCC6-0076 can produce OTA, while Aspergillus niger BLCC6-0007 does not produce OTA. Therefore, Aspergillus ochraceus BLCC6-0076 was selected as the OTA-producing Aspergillus ochraceus for subsequent experiments.

[0068] Antagonistic Effect of Brevibacillus laterosporus BLCC1-0170 on OTA-Producing Aspergillus ochraceus

[0069] The plate confrontation method was used to detect the antagonistic effect of Brevibacillus laterosporus BLCC1-0170 on OTA-producing Aspergillus ochraceus. The specific steps are as follows:

[0070] Six Aspergillus ochraceus BLCC6-0076 cakes were removed using a 1.00 cm diameter hole punch and transferred to the center of a new PDA medium plate. Three of the plates were inoculated with the antagonistic strain, Brevibacillus laterosporus BLCC1-0170, on both sides of the center. At the same time, three other PDA medium plates inoculated with Aspergillus ochraceus BLCC6-0076 cakes were placed in an incubator as controls. After incubation at 28°C for 5 days, the diameters of the Aspergillus ochraceus colonies on the plates were measured and the inhibition rates were calculated. The results are shown in Tables 3 and 4. Figure 2 As shown. Among them, the calculation formula of the inhibition rate is:

[0071] Inhibition rate = (control colony diameter - test colony diameter) / control colony diameter × 100%.

[0072] Table 3 Inhibitory effect of Brevibacillus laterosporus BLCC1-0170 on Aspergillus ochraceus BLCC6-0076

[0073]

[0074]

[0075] Depend on Figure 2 As shown in Table 3, Brevibacillus laterosporus BLCC1-0170 has a strong inhibitory effect on OTA-producing Aspergillus ochraceus. The average colony diameter obtained in the inhibition test is 0.57 cm, and the inhibition rate is as high as 82.35%.

[0076] 3 Scanning electron microscopy observation of OTA-producing Aspergillus ochraceus strains under antagonistic effects

[0077] Take a 2.5% mass fraction of glutaraldehyde fixative solution and slowly and evenly add it to the PDA culture dish after culture in step 2 above, and let the culture dish stand at room temperature for 24 hours. Then use a rubber-tipped dropper to gently aspirate the fixative solution into the waste liquid tank. After the fixative solution is dried, use a scalpel to cut off the Aspergillus ochraceus strain part in the culture medium for electron microscopy detection. The results are as follows: Figure 3 shown.

[0078] Depend on Figure 3 As can be seen from (b), the hyphae of Aspergillus ochraceus inhibited by Brevibacillus laterosporus BLCC1-0170 showed shrinkage, twisting, wrinkling, protoplasm rupture, thickening and deformity, and the spore production ability of the Aspergillus ochraceus strain was significantly reduced.

[0079] Example 3: Application of Brevibacillus laterosporus BLCC1-0170 in broiler chickens

[0080] 1 Test method

[0081] This study used 270 3-day-old white-feathered broiler chickens as experimental animals.

[0082] Before broiler chickens entered the henhouse, the floor, cages, feeders, and drinkers were cleaned and disinfected, and the cages and all equipment were fumigated. During the experiment, the temperature in the henhouse was controlled at 30±5°C and the relative humidity was 40%. The broilers were raised in double-layer cages to ensure free access to food and water. The cages were cleaned and wiped daily, and the feeders and drinkers were cleaned daily to ensure a good growth environment for the broilers.

[0083] A total of 270 white-feathered broiler chickens were randomly divided into three groups: a control group (CK group), an OTA group, and a combined OTA and antidote group (OTA+JY group). Each group had 6 replicates, with 15 chickens in each replicate. All broiler chickens were fed ad libitum with free access to feed and water. The experimental period was 21 days. The conventional feed was purchased from Shannong Agriculture and Animal Husbandry (Taian) Co., Ltd., and the OTA toxin was purchased from Qingdao Puruibang Bioengineering Co., Ltd. The specific treatment was as follows:

[0084] CK group: Purified water was used as drinking water and normal feed was consumed.

[0085] OTA group: Purified water was used as drinking water, and the feed consumed was ordinary feed mixed with OTA toxin evenly, with the added amount of OTA toxin in the feed being 0.05 mg / kg.

[0086] (OTA+JY) group: 1‰ (volume ratio) of Brevibacillus laterosporus BLCC1-0170 fermentation broth was added to purified water as drinking water, and the number of viable bacteria of Brevibacillus laterosporus BLCC1-0170 in the drinking water was adjusted to 1×10 6 cfu / mL, wherein the preparation method of the fermentation broth of Brevibacillus laterosporus BLCC1-0170 is the same as that in Example 1; the feed consumed is ordinary feed evenly mixed with OTA toxin, and the addition amount of OTA toxin in the feed is 0.05 mg / kg.

[0087] During the experimental period, the diets of each treatment group were freshly prepared every day during feeding, and other feeding and management conditions remained the same.

[0088] During the experiment, daily feed intake, body weight, and other physiological indicators were recorded. Five chickens from each replicate group were taken on the 7th, 14th, and 21st days after the start of the experiment. Venous blood was collected after fasting for 24 hours and the chickens were sacrificed. The kidneys and livers were immediately removed and washed with pre-chilled saline. The washed organs and tissues were dried with filter paper and stored at -20°C until further use. 0.5g of kidney and 0.5g of liver tissue were collected from each chicken and added to 4.5mL of pre-chilled acetonitrile solution. After thorough grinding, the mixture was shaken and incubated for 12 hours. The supernatant was centrifuged at 4000 rpm for 10 minutes, and the OTA content in the supernatant was determined by high-performance liquid chromatography.

[0089] After the venous blood was allowed to stand at 30°C for 30 minutes, it was centrifuged at 4000 rpm / min for 10 minutes, the supernatant was aspirated, and the various biochemical indicators in the serum were detected using a blood biochemical analyzer.

[0090] 2 Test results

[0091] 2.1 Effects on broiler growth performance

[0092] The results are shown in Table 4.

[0093] Table 4 Growth performance of broiler chickens in each experimental group

[0094] CK group OTA group (OTA+JY) group Initial weight (g) <![CDATA[67.52±0.88 a ]]> <![CDATA[67.81±1.02 a ]]> <![CDATA[68.21±1.46 a ]]> Final weight (g) <![CDATA[1035.56±19.86 a ]]> <![CDATA[965.85±21.75 b ]]> <![CDATA[1019.44±15.89 a ]]> Average daily weight gain (g / d) <![CDATA[46.09±2.89 a ]]> <![CDATA[42.76±4.27 b ]]> <![CDATA[45.30±3.89 ab ]]> Daily intake (g / d) <![CDATA[121.86±3.40 a ]]> <![CDATA[112.15±6.64 b ]]> <![CDATA[117.56±2.23 ab ]]>

[0095] Note: Data in the same row with different letters in the shoulder indicate significant differences (P<0.05), while data with the same letter or no letter in the shoulder indicate no significant differences (P>0.05).

[0096] As shown in Table 4, after 21 days of feeding, the final weight, daily intake and average daily gain of the OTA group were significantly lower than those of the control group (P < 0.05), the weight gain of broilers decreased, and the growth performance declined. This may be because the toxic effect of OTA leads to a decrease in broiler feed intake, and the absorption and synthesis capacity of the digestive system deteriorates, thus affecting the growth performance of broilers; while the final weight, daily intake and average daily gain of the (OTA+JY) group were not significantly different from those of the control group, indicating that Brevibacillus laterosporus BLCC1-0170 can alleviate the effect of OTA on broiler growth.

[0097] 2.2 Effects on broiler serum biochemical parameters

[0098] Table 5 Serum biochemical parameters of broiler chickens in each experimental group

[0099]

[0100] Note: Data in the same row with different letters in the shoulder indicate significant differences (P<0.05), while data with the same letter or no letter in the shoulder indicate no significant differences (P>0.05).

[0101] As shown in Table 5, after 21 days of feeding, the serum biochemical indicators of chickens showed that compared with the CK group, the ALT, AST, creatinine, uric acid and urea indicators of the OTA group were significantly increased (P < 0.05), indicating that the liver and kidney functions of the chickens in the OTA group were severely damaged; compared with the CK group, the ALT, AST, creatinine and urea indicators of the (OTA+JY) group were increased, but the difference was not significant; compared with the CK group, the albumin indicator of the OTA group was significantly increased (P < 0.05), and although the albumin in the (OTA+JY) group showed an increasing trend, the difference was not significant, which may be due to the impaired synthetic function of the liver of the broilers in the OTA group and the decreased filtration and reabsorption function of the kidneys; this shows that Brevibacillus laterosporus BLCC1-0170 can reduce the damage of OTA to the liver and kidneys of broilers to a certain extent.

[0102] 2.3 Effects on OTA toxin residues in broiler liver and kidney tissues

[0103] The results are as follows Figure 4 shown.

[0104] Depend on Figure 4OTA toxin residues were detected in the liver and kidney tissues of chickens in the OTA and (OTA+JY) groups at all three sampling periods, with highly significant differences compared to the CK group. Compared to the OTA group, after seven days of feeding the fermentation broth of B. laterosporus BLCC1-0170, the OTA content in the liver of the (OTA+JY) group decreased by 23.51% and the OTA content in the kidney decreased by 17.82%. After 14 days of feeding the fermentation broth of B. laterosporus BLCC1-0170, the OTA content in the liver of the (OTA+JY) group decreased significantly by 53.36% and the OTA content in the kidney decreased by 40.37%. After 21 days of feeding the fermentation broth of B. laterosporus BLCC1-0170, the OTA content in the liver of the (OTA+JY) group decreased significantly by 65.24% and the OTA content in the kidney decreased by 62.48%. These results indicate that B. laterosporus BLCC1-0170 has a good OTA degradation effect in animals.

[0105] The above description is merely a preferred embodiment of the present application and is not intended to limit the present application. Various modifications and variations are possible for those skilled in the art. Any modifications, equivalent substitutions, or improvements made within the spirit and principles of the present application shall be included within the scope of protection of the present application.

Claims

1. Use of Brevibacillus laterosporus in the following (1) or (2): (1) Degradation of ochratoxin A; (2) preparing a product for degrading ochratoxin A; The deposit number of the Brevibacillus laterosporus is CCTCC NO: M 2022932.

2. The use according to claim 1, characterized in that The Brevibacillus laterosporus participates in the degradation of ochratoxin A in the form of live bacteria or fermentation liquid.

3. The use according to claim 2, characterized in that The fermentation broth of Brevibacillus laterosporus is prepared by the following method: The Brevibacillus laterosporus was activated and inoculated into LB liquid culture medium, and fermented to obtain a fermentation liquid.

4. The use according to claim 3, characterized in that The fermentation temperature is 35-38°C, the fermentation speed is 150-200r / min, and the fermentation culture time is 12-36h.

5. The use according to claim 1, characterized in that The product for degrading ochratoxin A also includes auxiliary materials and / or carriers.

6. The use according to claim 1 or 5, characterized in that The dosage form of the product for degrading ochratoxin A is liquid, emulsion, suspension, powder, granule, wettable powder or water dispersant.

7. Use of Brevibacillus laterosporus in the preparation of an antibacterial product for Aspergillus ochraceus; the Brevibacillus laterosporus has a deposit number of CCTCC NO: M 2022932.

8. The use according to claim 7, characterized in that The Brevibacillus laterosporus inhibits the growth of Aspergillus ochraceus through at least one of the following pathways (1)-(3): (1) Inhibit the hyphae growth of Aspergillus ochraceus; (2) Promote protoplasm rupture; (3) Reduce the spore production ability of Aspergillus ochraceus.

Images